-
Ibritumomab tiuxetan (pronounced /ɪbrɪˈtuːmoʊmæb taɪˈʌksɛtæn/), sold
under the
trade name Zevalin, is a
monoclonal antibody radioimmunotherapy treatment...
-
Monoclonal antibody ibritumomab conjugated with
tiuxetan...
- A
radioligand is a
microscopic particle which consists of a
therapeutic radioactive isotope and the cell-targeting
compound - the ligand. The
ligand is...
-
yttrium (Y 90)
clivatuzumab tetraxetan (USAN)
yttrium (Y 90)
ibritumomab tiuxetan (INN)
yttrium bromatum yttrium fluoratum yttrium iodide yttrium metalli****...
- is not
accessible in
normal cells. 131I
tositumomab and 90Y
ibritumomab tiuxetan were the
first agents of radioimmunotherapy, and they were
approved for...
- yttrium-90 (90Y) is used to
label drugs such as
edotreotide and
ibritumomab tiuxetan for the
treatment of
various cancers,
including lymphoma, leukemia, liver...
-
triaminopentacarboxylate scaffold for
metal ions. In
ibritumomab tiuxetan, the
chelator tiuxetan is a
modified version of DTPA
whose carbon backbone contains...
- (131I)
tositumomab V10XX01
Sodium phosphate (32P) V10XX02
Ibritumomab tiuxetan (90Y) V10XX03
Radium (223Ra)
dichloride V10XX04
Lutetium (177Lu) oxodotreotide...
-
radiolabeling process,
which is
tailored to the
desired product.
Ibritumomab Tiuxetan;
Zevalin - For
dosimetry estimates prior to 90Y
immunotherapy for lymphoma...
-
release syndrome, hy****nsitivity and
electrolyte anomalies.
Ibritumomab tiuxetan IV CD20
antibody bound with the
radioactive isotope, 90Y,
induces radiation-dependent...
